Please login to the form below

Not currently logged in
Email:
Password:

Celixir cleared to start trial of stem cell therapy for heart failure

Previous trial demonstrated patients achieving 100% MACE free survival

heart

UK biotech Celixir has been given a green light to start a phase IIb trial of HeartCel - its stem cell-based therapy for heart failure - that could potentially support approval.

Heartcel is a preparation of off-the-shelf immunomodulatory progenitor (iMP) cells that are injected around cardiac scar tissue during coronary artery bypass graft (CABG) surgery in the hope of stimulating repair and preventing the heart from progressing to failure.

The therapy has already shown promise in a phase II trial in 11 patents reported at the 2016 International Society of Stem Cell Research meeting, achieving 100% major adverse cardiac event (MACE) free survival at 12 months as well as a 30% improvement in heart function, a 40% reduction in scar size and improvements in quality of life.

Since then, the study has reached the four-year follow-up point and patients remain the MACE-free survival rate remains at 100%, with imaging studies showing scar reduction and heart regeneration in 70% of patients, according to the biotech.

“Replicating these results in larger global trials with, could make Heartcel eligible for conditional marketing authorisation in Europe and FDA accelerated approval in the US,” said Celixir, which was previously known as Cell Therapy.

The phase IIb trial will be conducted at Imperial College London’s Royal Brompton, UK, and is expected to complete in 2020, setting up a potential approval the following year if all goes to plan.

The start of the trial will top off a fruitful period for Stratford-upon-Avon-based Celixir, which achieved an institutional funding round in 2017, picked up approval for its manufacturing unit and completed the application process to seek approval to start clinical trials in the US.

Heart failure is still a major cause of death affecting millions of patients worldwide [and] current therapies do not reduce chronic myocardial scarring, diminish disease progression or prolong life,” commented Prof Stephen Westaby, Celixir’s chief medical officer and a former consultant heart surgeon at the John Radcliffe Hospital in Oxford.

“The initial Heartcel trial results are very exciting, showing the first evidence in humans of disease reversal, scar reduction and heart regeneration. We are assembling a world-class team at Imperial College, in the US and in Asia to accelerate patients' access to this potential breakthrough in treatment of heart failure," he added.

Article by
Phil Taylor

10th January 2018

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....